Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
onartuzumab + sorafenib
- Development stage
- Phase 1
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
**Onartuzumab + sorafenib** is an investigational combination therapy for advanced hepatocellular carcinoma. Onartuzumab is a monoclonal antibody that targets the hepatocyte growth factor receptor (MET), inhibiting MET-mediated signaling pathways associated with tumor growth, angiogenesis, and metastasis. Sorafenib is a small molecule multi-kinase inhibitor blocking several kinases involved in cell proliferation (Raf kinases), angiogenesis (VEGFR, PDGFR), and tumor progression. The combination seeks to simultaneously inhibit tumor cell signaling and angiogenesis, aiming for enhanced antitumor activity compared to monotherapy.
- Brand names
- Nexavar
- Other names
- onartuzumab + sorafenibMetMAb + sorafenibRG7285 + BAY 43-9006
02
Targets
BRAF (B-Raf proto-oncogene, serine/threonine kinase)MET (Mesenchymal-epithelial transition factor receptor)RAF1 (c-Raf-1 (Y340D/Y341D))PDGFR (PDGFR family)VEGFR (VEGFR family)
Beyond the preview
Go deeper on onartuzumab + sorafenib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on onartuzumab + sorafenib.